Patents Assigned to Peregrine Pharmaceuticals, Inc.
-
Patent number: 9835626Abstract: Disclosed are surprising new methods and compositions for isolating extracellular microvesicles such as exosomes, particularly disease-related and phosphatidylserine (PS)-positive extracellular microvesicles as exemplified by tumor- and viral-derived exosomes. The methods of the invention are rapid, efficient, cost-effective and, importantly, are suitable for use with large volumes of biological fluids and produce antigenically intact extracellular microvesicles and exosomes. The methods and compositions are based on the surprising use of acetate buffers to isolate large quantities of extracellular microvesicles, particularly tumor-derived exosomes, from solution, without damaging their morphological or functional properties or antigenicity.Type: GrantFiled: February 27, 2015Date of Patent: December 5, 2017Assignees: Board of Regents, The University of Texas System, Peregrine Pharmaceuticals, Inc.Inventors: Alan J. Schroit, Philip E. Thorpe, Shelley P. M. Fussey
-
Patent number: 9421256Abstract: Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.Type: GrantFiled: February 15, 2013Date of Patent: August 23, 2016Assignees: Affitech Research AS, Peregrine Pharmaceuticals, Inc.Inventors: Anita Kavlie, Kyle Schlunegger
-
Patent number: 8956616Abstract: Disclosed are new phosphatidylserine binding constructs with surprising combinations of properties, and a range of diagnostic and therapeutic conjugates thereof. The new constructs effectively bind phosphatidylserine targets in disease and enhance their destruction, and can also specifically deliver attached imaging or therapeutic agents to the disease site. Also disclosed are methods of using the new construct compositions, therapeutic conjugates and combinations thereof in tumor vasculature targeting, cancer diagnosis and treatment, and for treating viral infections and other diseases.Type: GrantFiled: January 24, 2006Date of Patent: February 17, 2015Assignees: Board of Regents, The University of Texas System, Peregrine Pharmaceuticals, Inc.Inventors: Philip E. Thorpe, Troy A. Luster, Steven W. King
-
Publication number: 20130149238Abstract: Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.Type: ApplicationFiled: February 15, 2013Publication date: June 13, 2013Applicants: PEREGRINE PHARMACEUTICALS, INC., AFFITECH RESEARCH ASInventors: AFFITECH RESEARCH AS, PEREGRINE PHARMACEUTICALS, INC.
-
Patent number: 8394943Abstract: Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.Type: GrantFiled: September 6, 2011Date of Patent: March 12, 2013Assignees: Affitech Research AS, Peregrine Pharmaceuticals, Inc.Inventors: Anita Kavlie, Kyle Schlunegger
-
Patent number: 8137540Abstract: Disclosed are improved methods and apparatus for radiolabeling, particularly methods and apparatus for large scale in-line radiolabeling of products, such as proteins and antibodies.Type: GrantFiled: August 20, 2009Date of Patent: March 20, 2012Assignee: Peregrine Pharmaceuticals, Inc.Inventors: Raimo Pellikka, Steven W. King, Peter Bläuenstein, Pius A. Schubiger
-
Publication number: 20120064001Abstract: Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.Type: ApplicationFiled: September 6, 2011Publication date: March 15, 2012Applicants: AFFITECH RESEARCH AS, PEREGRINE PHARMACEUTICALS, INC.Inventors: Anita Kavlie, Kyle Schlunegger
-
Patent number: 8034905Abstract: Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.Type: GrantFiled: November 7, 2008Date of Patent: October 11, 2011Assignees: Affitech Research, AS, Peregrine Pharmaceuticals, Inc.Inventors: Anita Kavlie, Kyle Schlunegger
-
Patent number: 7605234Abstract: Specific binding members, featuring certain residues of the third CDR of the antibody NH576 (portions of SEQ ID NO:2) are provided, together with their use in methods of treatment and diagnosis.Type: GrantFiled: July 13, 2004Date of Patent: October 20, 2009Assignee: Peregrine Pharmaceuticals, Inc.Inventors: Andrew James Williams, Philip Ronald Tempest, Thor Las Holtet, Helen Jackson
-
Patent number: 7591953Abstract: Disclosed are improved methods and apparatus for radiolabeling, particularly methods and apparatus for large scale in-line radiolabeling of products, such as proteins and antibodies.Type: GrantFiled: June 25, 2004Date of Patent: September 22, 2009Assignee: Peregrine Pharmaceuticals, Inc.Inventors: Raimo Pellikka, Steven W. King, Peter Bläuenstein, Pius A. Schubiger
-
Publication number: 20090175791Abstract: Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.Type: ApplicationFiled: November 7, 2008Publication date: July 9, 2009Applicants: Peregrine Pharmaceuticals, Inc., Affitech A/SInventors: Anita Kavile, Kyle Schlunegger
-
Publication number: 20030139374Abstract: Disclosed are various defined combinations of agents for use in improved anti-vascular therapies and coagulative tumor treatment. Particularly provided are combined treatment methods, and associated compositions, pharmaceuticals, medicaments, kits and uses, which together function surprisingly effectively in the treatment of vascularized tumors. The invention preferably involves a component or treatment step that enhances the effectiveness of therapy using targeted or non-targeted coagulants to cause tumor vasculature thrombosis.Type: ApplicationFiled: September 27, 2002Publication date: July 24, 2003Applicant: Board of Regents, The University of Texas System and Peregrine Pharmaceuticals, Inc.Inventors: Philip E. Thorpe, Steven W. King, Claudia Gottstein
-
Publication number: 20030129193Abstract: Disclosed are various defined combinations of agents for use in improved anti-vascular therapies and coagulative tumor treatment. Particularly provided are combined treatment methods, and associated compositions, pharmaceuticals, medicaments, kits and uses, which together function surprisingly effectively in the treatment of vascularized tumors. The invention preferably involves a component or treatment step that enhances the effectiveness of therapy using targeted or non-targeted coagulants to cause tumor vasculature thrombosis.Type: ApplicationFiled: September 27, 2002Publication date: July 10, 2003Applicant: Board of Regents, The University of Texas System and Peregrine Pharmaceuticals, Inc.Inventors: Philip E. Thorpe, Steven W. King, Claudia Gottstein
-
Patent number: 6255291Abstract: A composition containing alph-alanine, adenosine compound and a glucan. Methods for treating cancer and immunological disorders with said composition.Type: GrantFiled: February 27, 1998Date of Patent: July 3, 2001Assignee: Peregrine Pharmaceuticals, Inc.Inventor: Yveta Germano
-
Patent number: 5879880Abstract: A method for determining whether a mammal should be medically investigated for a cancerous or pre-cancerous condition based upon the formic acid to nicotinic acid ratio in the blood of the mammal.Type: GrantFiled: April 25, 1997Date of Patent: March 9, 1999Assignee: Peregrine Pharmaceuticals, Inc.Inventors: Jaroslav Koca, Yveta Germano, Vaclav Racansky